Presentation data outlines PD/PK relationship and safety margins for next-generation psychedelics TORONTO, Nov. 08, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company“), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders…

Source

Previous articlePTSF84 – A Brief Check-in From Wonderland
Next articlePsychedelic Bulletin: Deconstructing COMPASS Pathways’ Phase 2b Results